Biodesix develops and commercializes blood-based diagnostics to answer unmet clinical questions across the lung cancer continuum of care.
1 in 15 people in the U.S. will be diagnosed with lung cancer in their lifetime—1 in 14 men and 1 in 17 women.
Source: SEER Cancer Statistics Review 1975-2012, Cancer of the Lung and Bronchus, Tables 15.18-15.20
We are committed to improving the lives of patients with lung cancer through our on-market products and development pipeline.
Biodesix Lung Reflex®
By integrating genomic and proteomic blood-based results in 72 hours, we see both sides of lung cancer. These results can facilitate patient conversations and treatment strategies.